| Name | Title | Contact Details |
|---|
Build no-code apps for your mobile and deskless workforce. Launch in days. Scale and build more apps, from 10 to 10,000.
Explore your research potential with data to analyze, discover, and connect from Academic Analytics, the best analytics for university research management.
SMS Marketing | E-Commerce Marketing | Mobile Commerce Powerful SMS marketing campaigns and more with a suite of Mobile Commerce tools.
Monitor, observe, analyze, and explain your machine learning models in production with Fiddler AI. Maximize ML model performance with our Model Performance Management Platform that simply plugs in.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.